Sunshine Biopharma Enters Into a Collaboration Agreement With a Leading Lipid Nanoparticle Formulation Company for Its K1.1 Anticancer MRNA Project
Sunshine Biopharma Enters Into a Collaboration Agreement With a Leading Lipid Nanoparticle Formulation Company for Its K1.1 Anticancer MRNA Project
MONTREAL, Nov. 16, 2022 (GLOBE NEWSWIRE) -- Sunshine Biopharma Inc. (NASDAQ: "SBFM"), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas, including oncology and antivirals today announced that it has entered into a collaboration agreement with one of North America's leading lipid nanoparticle ("LNP") companies. The purpose of the collaboration is to advance the development of Sunshine Biopharma's mRNA-based anticancer macromolecule, K1.1.
蒙特利尔，2022年11月16日(环球网)--阳光生物制药公司(纳斯达克代码：“SBFM”)，一家在肿瘤和抗病毒药物等多种治疗领域提供和研究救命药物的制药公司今天宣布，它已与北美领先的脂质纳米粒(“LNP”)公司之一达成合作协议。合作的目的是推进阳光生物制药基于mRNA的抗癌大分子K1.1的开发。
The Company's collaboration partner will prepare two LNP formulations (K1.1a and K1.1b) of Sunshine Biopharma's in-house developed antineoplastic mRNA, K1.1. Sunshine Biopharma had previously shown that its K1.1 mRNA is capable of destroying cancer cells in vitro, including multidrug resistant breast cancer cells (MCF-7/MDR), ovarian adenocarcinoma cells (OVCAR-3), and pancreatic cancer cells (SUIT-2). Parallel studies using normal human cells (HMEC) showed that K1.1 mRNA had little or no cytotoxic effects.
该公司的合作伙伴将为阳光生物制药公司内部开发的抗肿瘤信使核糖核酸K1.1准备两种LNP配方(K1.1a和K1.1b)。阳光生物制药公司此前已证明，其K1.1 mRNA能够在体外摧毁癌细胞，包括多药耐药乳腺癌细胞(MCF-7/MDR)、卵巢腺癌细胞(OVCAR-3)和胰腺癌细胞(Suit-2)。用正常人细胞(HMEC)进行的平行研究表明，K1.1mRNA几乎没有或没有细胞毒作用。
The partner generated K1.1a::LNP and K1.1b::LNP will be used to conduct in vivo studies on xenograft mice expressing the in vitro tested human cancers as well as liver cancer. Should these mice studies prove successful, the Company can advance relatively rapidly to conducting human trials. The LNP formulated K1.1 mRNA can be readily adapted for delivery into patients using the recently gained knowledge from the mRNA vaccine technology.
产生K1.1a：：LNP和K1.1b：：LNP的伙伴将用于在异种移植鼠身上进行体内研究，表达体外测试的人类癌症以及肝癌。如果这些小鼠研究被证明是成功的，该公司可以相对较快地推进进行人体试验。利用最近从信使核糖核酸疫苗技术中获得的知识，LNP配制的K1.1信使核糖核酸可以很容易地被改造成输送到患者体内。
"We are delighted to be working with our new partner and their fully integrated team of experts in LNP technology," said Dr. Steve Slilaty, CEO of Sunshine Biopharma.
阳光生物制药公司首席执行官史蒂夫·斯莱拉蒂博士说：“我们很高兴能与我们的新合作伙伴以及他们在LNP技术方面完全整合的专家团队合作。
About Sunshine Biopharma Inc.
阳光生物医药公司简介
Sunshine Biopharma recently acquired Nora Pharma Inc. and as a result the Company now has 36 employees and 50 generic prescription drugs on the market in Canada. In parallel, Sunshine Biopharma is continuing its drug development R&D program. In addition to the K1.1 anticancer mRNA project, the Company is working on the development Adva-27a, a small molecule having the unique ability to destroy multidrug resistant cancer cells, including pancreatic cancer cells, small-cell lung cancer cells, breast cancer cells, and uterine sarcoma cells. Clinical trials for pancreatic cancer indication are planned to be conducted at McGill University's Jewish General Hospital in Montreal, Canada. Sunshine Biopharma is also engaged in the development of a COVID-19 treatment in collaboration with the University of Arizona. The project, currently in advanced stages of preclinical studies, is focused on the development of an inhibitors for SARS-CoV-2 PLpro protease. PLpro is unique to the SARS group of Coronaviruses and is responsible for suppressing the human immune system making this group of viruses more deadly.
阳光生物制药公司最近收购了Nora Pharma Inc.，因此，该公司目前在加拿大市场上有36名员工和50种非专利处方药。与此同时，阳光生物医药公司正在继续其药物开发研发计划。除了K1.1抗癌基因项目外，该公司还致力于开发Adva-27A，这是一种具有独特能力的小分子，可以摧毁多药耐药癌细胞，包括胰腺癌细胞、小细胞肺癌细胞、乳腺癌细胞和子宫肉瘤细胞。胰腺癌适应症的临床试验计划在加拿大蒙特利尔的麦吉尔大学犹太综合医院进行。阳光生物制药公司还与亚利桑那大学合作，参与了新冠肺炎疗法的开发。该项目目前处于临床前研究的后期阶段，重点是开发一种SARS-CoV-2 PLPro蛋白酶的抑制剂。PLPro是SARS冠状病毒组所特有的，负责抑制人类免疫系统，使这组病毒更致命。
Safe Harbor Forward-Looking Statements
安全港前瞻性陈述
This press release contains forward-looking statements which are based on current expectations, forecasts, and assumptions of Sunshine Biopharma, Inc. (the "Company") that involve risks as well as uncertainties that could cause actual outcomes and results to differ materially from those anticipated or expected. These statements appear in a number of places in this release and include all statements that are not statements of historical fact regarding the intent, belief or current expectations of the Company, including statements related to the Company's drug development activities, financial performance, and future growth. These risks and uncertainties are further described in filings and reports by the Company with the U.S. Securities and Exchange Commission (SEC). Actual results and the timing of certain events could differ materially from those projected in or contemplated by the forward-looking statements due to a number of factors detailed from time to time in the Company's filings with the SEC. Reference is hereby made to cautionary statements and risk factors set forth in the Company's most recent SEC filings.
本新闻稿包含前瞻性陈述，这些陈述基于阳光生物医药公司(“本公司”)目前的预期、预测和假设。这些前瞻性陈述涉及风险和不确定因素，可能导致实际结果和结果与预期或预期的大不相同。这些陈述出现在本新闻稿的许多地方，包括所有与公司的意图、信念或当前预期有关的非历史事实的陈述，包括与公司的药物开发活动、财务业绩和未来增长有关的陈述。这些风险和不确定性在该公司提交给美国证券交易委员会(美国证券交易委员会)的文件和报告中有进一步的描述。某些事件的实际结果和时间可能与前瞻性陈述中预测的或预期的大不相同，原因是公司在提交给美国证券交易委员会的文件中不时详述的一些因素。兹参考本公司最近提交给美国证券交易委员会的文件中的警告性声明和风险因素。
For Additional Information:
有关其他信息，请访问：
Sunshine Biopharma Contact:
Camille Sebaaly, CFO
Direct Line: 514-814-0464
camille.sebaaly@sunshinebiopharma.com
阳光Biophma联系方式：
首席财务官卡米尔·塞巴利
直拨电话：514-814-0464
邮箱：camille.sebaaly@sunshinebiopharma.com
Sunshine Biopharma Media Contact:
Christine Petraglia
TraDigital IR
Direct Line: 917-633-8980
investors@sunshinebiopharma.com
阳光Biophma媒体联系人：
克里斯汀·佩特拉格里亚
曲吉红外线
直拨电话：917-633-8980
邮箱：Investors@sunshinebiopharma.com